Editing
Metastatic Kidney Cancer
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Questions == # What are the IMDC criteria and the risk groups? # Describe how CARMENA and SURTIME have influence the role of CN? # As per the 2019 CUA Consensus Statement on CN, what are the criteria for offering upfront CN? # What does nivolumab target? Ipilimumab? # List VEGF inhibitors used in RCC. # List mTOR inhibitors used in RCC. # What is the first-line systemic treatment in metastatic ccRCC?
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information